AOAysel Unver Ozkahraman

Aysel Unver Ozkahraman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aysel Unver Ozkahraman has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Peripheral leukocyte profiles in different clinical forms of hypercortisolism and nonfunctioning adrenal tumors: a retrospective cross-sectional study

    by Sebnem Burhan, Aysel Unver Ozkahraman, Merve Korkmaz Yilmaz, Sezer Akbulut, Muhammed Zeki Cicek, Mutlu Niyazoglu, Esra Hatipoglu

  • Open Access

    Clinicopathological features and outcomes of immature PIT-1 lineage tumors: A high-risk pituitary neuroendocrine tumor/pituitary adenoma subtype per WHO 2022

    by Aysel Unver Ozkahraman, Aslihan Pekmezci, Huseyin Karatay, Ebubekir Akpinar, Buruc Erkan, Mehmet Karagulle, Burak Kocak, Mutlu Niyazoglu, Esra Hatipoglu

    Purpose: Immature PIT-1 lineage tumors are classified as high-risk pituitary adenomas/pituitary neuroendocrine tumors (PitNETs) under the 2022 WHO Classification, yet clinical outcome data remain scarce. This study aimed to characterize clinicopathological features and treatment outcomes of this rare entity. Methods: We retrospectively analyzed 13 patients with pathologically confirmed immature PIT-1 lineage tumors who underwent surgery at our tertiary center between January 2022 and December 2024. Diagnoses were established according to WHO 2022 criteria using comprehensive transcription factor (TF) immunohistochemistry. Clinical, radiological, histopathological, treatment, and follow-up data were evaluated. Results: Immature PIT-1 lineage tumors accounted for 4% (21/525) of surgically treated pituitary adenomas, of whom 13 with complete follow-up data constituted the primary analysis cohort. Median age was 37 years (range: 25–73), with female predominance (61.5%). Notably, 61.5% presented with hormonal hypersecretion: acromegaly (38.5%), TSH-secreting tumors (15.4%), and GH-PRL co-secretion (7.7%). All patients had macroadenomas (median diameter 28 mm (range: 15–59 mm)); 38.5% demonstrated cavernous sinus invasion (Knosp grades 3–4). Immunohistochemically defined plurihormonal phenotype was present in 77% of cases; cytologic atypia was identified in all cases. Despite maximal surgical resection, residual disease persisted in 46% and 31% required reoperation at 16-month follow-up (range: 4–51 months). The median Ki-67 proliferation index was 4% (IQR: 2–10%; range: 1–35%), and the median mitotic count was 4 per 2 mm² (IQR: 1–8; range: 1–20). Conclusion: Immature PIT-1 lineage tumors exhibit aggressive behavior with high residual disease rates, with 31% of patients requiring reoperation, 23% receiving adjuvant radiotherapy, and somatostatin analogue resistance observed in two patients. Routine TF immunohistochemistry is essential for accurate diagnosis; management requires maximal safe surgical resection and intensive long-term surveillance.

  • Open Access

    Skeletal assessment in giant prolactinoma: a reply

    by Aysel Unver Ozkahraman, Esra Hatipoglu

    Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.

  • Multimodal management of giant prolactinoma with extensive amyloid spherule deposition: a case report with review of the literature

    by Aysel Unver Ozkahraman, Merve Korkmaz Yilmaz, Huseyin Karatay, Sidar Bagbudar, Ebubekir Akpinar, Buruc Erkan, Mehmet Karagulle, Mesut Yilmaz, Mutlu Niyazoglu, Esra Hatipoglu

    Amyloid spherule-containing prolactinomas are rare entities associated with dopamine agonist (DA) resistance and aggressive behaviour. We report a giant amyloid spherule-containing prolactinoma with a substantial tumour burden and markedly elevated prolactin levels, highlighting novel multimodal therapeutic strategies. A 49-year-old man presented with headache and visual disturbance. Imaging revealed a giant pituitary macroadenoma (63 × 84 × 46 mm) with Knosp grade 4 cavernous sinus invasion and clivus erosion. Laboratory investigations revealed marked hyperprolactinemia (prolactin (PRL): 30,969 ng/mL) and autonomous growth hormone (GH) hypersecretion. Histopathology confirmed a sparsely granulated lactotroph tumour with extensive amyloid spherules and dystrophic calcifications (Ki-67: 8%). Notably, immunohistochemistry demonstrated PRL positivity without GH immunoreactivity, suggesting tumour heterogeneity with sampling limitations. Comprehensive systemic amyloidosis screening, the first systematic evaluation reported for this entity, excluded systemic disease. Following surgical debulking with extensive residual disease, postoperative cabergoline treatment resulted in a reduction in the PRL (4,700→927 ng/mL). Given the presence of amyloid-associated dopamine resistance, cabergoline was discontinued, and radiotherapy (RT) (45 Gy) was initiated to control the amyloid burden, followed by temozolomide. Based on evidence from other malignancies suggesting RT-mediated amyloid reduction, cabergoline was reintroduced postradiotherapy without paradoxical tumour growth. Concurrent cabergoline-temozolomide therapy, a novel approach that differs from conventional sequential protocols, achieved a dramatic response: 93.4% prolactin reduction (10,320→677 ng/mL) and 52.4% tumour volume reduction. This superior outcome far exceeded that of initial postsurgical cabergoline monotherapy (80% reduction), suggesting that RT successfully modulated the amyloid burden and restored dopamine sensitivity. This case suggests that RT may restore dopamine agonist sensitivity in patients with amyloid-containing prolactinomas, potentially enabling concurrent dopamine agonist-temozolomide therapy in refractory cases, warranting further validation.